found that 9p21 loss, normally CDKN2A (13.5%) and MTAP (9.3%), confers a cold tumor immune microenvironment, poor clinical outcomes, and primary resistance to immune checkpoint therapy for cancers (31). This evidence concerns the gene MTAP and neoplasm.